Skip to main content
Premium Trial:

Request an Annual Quote

Progenitor and Cambridge Antibody Form Collaboration

Premium

MENLO PARK, Calif.--Progenitor, a developer of genomics drug leads, announced a collaboration agreement with Cambridge Antibody, a British biotech firm that holds technology for the rapid isolation of human monoclonal antibodies that has applications as a drug discovery tool in functional genomics. The two firms said the arrangement will allow them to accelerate their respective product development programs by sharing elements of each other's technologies. Progenitor will give Cambridge Antibody access to novel genes as targets for antibody-based therapeutics, and will get new antibody-based functional genomics tools to characterize gene discoveries from Cambridge Antibody.

Progenitor CEO Douglass Given said the collaboration expands his firm's functional genomics capabilities, "and provides an unprecedented opportunity to move numerous gene discoveries quickly through target validation and into drug development programs."

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.